NES and neoplasm: In particular, Calabrese et al., treating mice carrying xenografts of U87 glioma cells with bevacizumab, reported a decrease in the number of CD133+/Nestin+ tumor initiation cells, a fall in microvasculature density, and a decrease in tumor growth [95].